How to buy Neoleukin Therapeutics stock

Neoleukin Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 65 staff and has a market cap (total outstanding shares value) of USD$498.2 million.

How to buy shares in Neoleukin Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Neoleukin Therapeutics. Find the stock by name or ticker symbol: NLTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neoleukin Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neoleukin Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Neoleukin Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. NLTX shares summary
2. Compare share dealing platforms
3. Is NLTX stock a buy or sell?
4. Stock performance over time
5. Can I short NLTX shares?
6. Neoleukin Therapeutics's financials
7. How volatile are NLTX shares?
8. Does Neoleukin Therapeutics pay a dividend?
9. Other common questions

Neoleukin Therapeutics share price

Use our graph to track the performance of NLTX stocks over time.

Neoleukin Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-02.

52-week range	USD$5.81 - USD$18.13
50-day moving average	USD$13.114
200-day moving average	USD$12.5906
Wall St. target price	USD$22.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.938

Buy Neoleukin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neoleukin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neoleukin Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Neoleukin Therapeutics shares

There are currently 3.2 million Neoleukin Therapeutics shares held short by investors – that's known as Neoleukin Therapeutics's "short interest". This figure is 7.7% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting Neoleukin Therapeutics shares can be evaluated.

Neoleukin Therapeutics's "short interest ratio" (SIR)

Neoleukin Therapeutics's "short interest ratio" (SIR) is the quantity of Neoleukin Therapeutics shares currently shorted divided by the average quantity of Neoleukin Therapeutics shares traded daily (recently around 244580.15209125). Neoleukin Therapeutics's SIR currently stands at 13.15. In other words for every 100,000 Neoleukin Therapeutics shares traded daily on the market, roughly 13150 shares are currently held short.

However Neoleukin Therapeutics's short interest can also be evaluated against the total number of Neoleukin Therapeutics shares, or, against the total number of tradable Neoleukin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neoleukin Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Neoleukin Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0898% of the tradable shares (for every 100,000 tradable Neoleukin Therapeutics shares, roughly 90 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Neoleukin Therapeutics.

Find out more about how you can short Neoleukin Therapeutics stock.

Neoleukin Therapeutics share price volatility

Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $5.81 up to $18.13. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 1.0043. This would suggest that Neoleukin Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Neoleukin Therapeutics overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Frequently asked questions

• What percentage of Neoleukin Therapeutics is owned by insiders or institutions?

  Currently 20.293% of Neoleukin Therapeutics shares are held by insiders and 66.216% by institutions.

• How many people work for Neoleukin Therapeutics?

  Latest data suggests 65 work at Neoleukin Therapeutics.

• When does the fiscal year end for Neoleukin Therapeutics?

  Neoleukin Therapeutics's fiscal year ends in December.

• Where is Neoleukin Therapeutics based?

  Neoleukin Therapeutics's address is: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102

• What is Neoleukin Therapeutics's ISIN number?

  Neoleukin Therapeutics's international securities identification number is: US64049K1043

• What is Neoleukin Therapeutics's CUSIP number?

  Neoleukin Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03842B101